Chesterford Research Park is aiming to fill the space gap between start-ups and established life science companies by providing up to 37,500 sq ft of fully fitted laboratory and admin space. Construction on the Newnham Building will begin in January and is scheduled for completion in May 2020.
Ideal for occupiers looking for grow-on space, the Newnham Building will create a detached two-storey laboratory/R&D building situated within a prominent position on the Park. The building will also provide 111 parking spaces.
“The Newnham Building’s prominent position on the Park, coupled with Chesterford’s excellent reputation within the cluster has meant we have already seen significant interest from current occupiers looking for grow-on space, as well as from ventures new to Chesterford Research Park. We very much look forward to seeing work on site commence in January.”
The Churchmanor Estates Company Plc
Newnham Building in an advantageous position
Situated in the London-Stansted-Cambridge corridor and alongside the Cambridge biotech cluster, the Newnham building will provide Life Sciences and Healthcare companies with direct access to world-class people, knowledge, funding and collaborative networks, at significantly lower cost than either Cambridge or London can offer.
Significant plant loft space makes the building capable of being occupied by a range of laboratory/R&D occupiers, either in part or as a whole. The flexibility of the building also gives it the capability to cater for a range of needs in terms of technical configuration, as well as sizing.
“There is a clear requirement within the cluster for additional grow-on space and the Newnham Building will offer that next step up for companies looking to expand. The flexibility of the space makes it suitable for either single or multi-occupier layout and the fully-fitted nature of the laboratory space adds a level of plug-and-play convenience rarely seen at this level. Bringing forward the Newnham Building at this stage responds to the needs of a growing market and clearly bridges the gap between pure start-up space and the larger, more established life-science ventures.”
Senior Asset Manager
About Chesterford Research Park
Chesterford Research Park provides an innovative, flexible and future proofed environment for both established and early stage biotechnology and pharmaceutical research and development companies including Arecor, AstraZeneca, Charles River Laboratories, Evonetix and Domainex.
More than 300,000 sq ft of laboratory R&D space has been let and occupied. Further phases of construction are proposed to extend the development to approximately 1 million sq ft. See here for more info.
The Park offers not only ultra-modern and energy efficient laboratory and office space, but also central ‘hub’ facilities within the purpose-built The Nucleus building. At the heart of the Park, the Nucleus houses a restaurant, café bar, health and fitness centre, and meeting and conferencing space, all of which can be accessed and enjoyed by both occupiers and visitors daily.
See here for more info on Chesterford Research Park
Visit Chesterford Research Park’s website here
Source: [Chesterford Research Park]